Skip to content
Peregrine
  • Home
  • About Us
    • Company Overview
    • Our Mission
  • Our Funds
  • Portfolio
  • Team
  • ESG & Impact
  • News
  • Contact
  • Home
  • About Us
    • Company Overview
    • Our Mission
  • Our Funds
  • Portfolio
  • Team
  • ESG & Impact
  • News
  • Contact

Amit Alfasi

Merck

Nectin Therapeutics has added a KEYTRUDA® Combination Therapy Arm and Expands Sites in Phase 1 Clinical Trial

Read More
Catiheal - Nir Altschuler

CartiHeal, makes biggest Israeli biomed exit of 2023

Read More

BioProtect Balloon ImplantTM System has been cleared by the FDA

Read More
Cordio Medical

AstraZeneca launches pilot program for Cordio Medical

Read More
KAHR

KAHR Medical reports dose escalation data from its Phase I trial of DSP107

Read More
FORBES

“It’s a simple daily habit that could save their life” – Cordio Medical coverage in Forbes magazine

Read More
RIBON

Ribon Therapeutics announced dosing of the first patient

Read More

Restore announces successful First-In-Human preliminary results of Its CONTRABAND™ system

Read More

BioProtect presented successful outcomes from its phase I/II study

Read More
Levation Pharma

Levation Pharma, Ltd. received an FDA clearance to initiate Phase I/II of LEV102

Read More
Page1 Page2 Page3 Page4 Page5
  • Homepage
  • About Us
  • Our Funds
  • Portfolio
  • Team
  • ESG AND IMPACT
  • News
  • Contact
  • Homepage
  • About Us
  • Our Funds
  • Portfolio
  • Team
  • ESG AND IMPACT
  • News
  • Contact
Linkedin-in
  • Terms of Use
  • Privacy Policy
  • Accessibility Statment
  • Cookie Policy
  • Terms of Use
  • Privacy Policy
  • Accessibility Statment
  • Cookie Policy
©All rights reserved to Peregrine 2026

site by: 

razgroup-logo
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}